<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03527875</url>
  </required_header>
  <id_info>
    <org_study_id>2018ZSLC24</org_study_id>
    <nct_id>NCT03527875</nct_id>
  </id_info>
  <brief_title>Process Optimization of Preoperative Biliary Drainage in Patients With Malignant Obstructive Jaundice</brief_title>
  <official_title>Process Optimization of Preoperative Biliary Drainage in Patients With Malignant Obstructive Jaundice of Extrahepatic Bile Duct: A Multi-center, Prospective, Open-labeled, Real World Study Based on Electronic Data Capture System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of different methods of
      preoperative biliary drainage in patients with extrahepatic bile duct neoplasms with
      obstructive jaundice (hilar cholangiocarcinoma, distal bile duct cancer, and periampullary
      carcinoma), including PTBD (Percutaneous Transhepatic Biliary Drainage), ENBD (Endoscopic
      Nasobiliary Drainage) and EBS (Endoscopic Biliary Stenting).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2018</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complication rate after drainage</measure>
    <time_frame>From PBD to completion of radical surgery, an average of 1 month</time_frame>
    <description>Complication rate between PBD (preoperative biliary drainage) and radical surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complication rate after radical surgery</measure>
    <time_frame>1 month post operatively</time_frame>
    <description>Complication rate after radical surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Success rate of PBD</measure>
    <time_frame>Day 1</time_frame>
    <description>Success rate of different methods of PBD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>operative time</measure>
    <time_frame>Day 1</time_frame>
    <description>duration of radical surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatoduodenal edema</measure>
    <time_frame>at time of radical surgery</time_frame>
    <description>Degree of hepatoduodenal edema (including no edema, mild edema, moderate edema, and severe edema)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative mortality</measure>
    <time_frame>from PBD to 4 weeks after surgery, an average of 2 month</time_frame>
    <description>Mortality between PBD and 4 weeks after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>implantation metastasis</measure>
    <time_frame>Day 1</time_frame>
    <description>Rate of implantation metastasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in Total bilirubin</measure>
    <time_frame>2 weeks after PBD</time_frame>
    <description>Recovery efficiency of liver function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in alanine aminotransferase</measure>
    <time_frame>2 weeks after PBD</time_frame>
    <description>Recovery efficiency of liver function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in aspartate aminotransferase</measure>
    <time_frame>2 weeks after PBD</time_frame>
    <description>Recovery efficiency of liver function</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">564</enrollment>
  <condition>Jaundice, Obstructive</condition>
  <condition>Klatskin Tumor</condition>
  <arm_group>
    <arm_group_label>PTBD group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Percutaneous Transhepatic Biliary Drainage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ENBD group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endoscopic Nasobiliary Biliary Drainage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EBS group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endoscopic Biliary Stenting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Without PBD group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>receive surgery without PBD</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PTBD group</intervention_name>
    <description>Percutaneous Transhepatic Biliary Drainage, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients</description>
    <arm_group_label>PTBD group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ENBD group</intervention_name>
    <description>Endoscopic Nasobiliary Drainage, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients</description>
    <arm_group_label>ENBD group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>EBS group</intervention_name>
    <description>Endoscopic Biliary Stenting, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients</description>
    <arm_group_label>EBS group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who meet the following four criteria are included into the study:

               1. Preoperative clinical diagnosis of hilar cholangiocarcinoma, distal bile duct
                  cancer, periampullary cancer without distant metastasis or peripheral vascular
                  invasion, and plan for radical surgery;

               2. Serum total bilirubin is higher than 51 umol/l;

               3. Age is older than 18 and younger than 80 years old;

               4. Sign in informed consent to receive preoperative PTBD, ENBD, EBS or without PBD.

        Exclusion Criteria:

          -  If any of the following items are met, the subject cannot enter the study.

               1. Incorporate severe mental illness, severe heart, lungs and kidneys disease, etc.,
                  and be unable to tolerate surgery;

               2. Malignant obstructive jaundice caused by metastatic tumors;

               3. Pregnancy or lactation women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Houbao Liu, PHD</last_name>
    <phone>13818971698</phone>
    <email>houbaoliu@aliyun.com</email>
  </overall_contact>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>April 23, 2018</study_first_submitted>
  <study_first_submitted_qc>May 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2018</study_first_posted>
  <last_update_submitted>June 1, 2018</last_update_submitted>
  <last_update_submitted_qc>June 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Klatskin Tumor</mesh_term>
    <mesh_term>Jaundice</mesh_term>
    <mesh_term>Jaundice, Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

